Crownsville Hospital Center

ASK LLP Files Lawsuit on Behalf of Former Patient at Crownsville State Hospital

Retrieved on: 
Friday, March 1, 2024
Complaint, Child, Crownsville Hospital Center, Woman, Survivor, Multimedia, Work, Injury, Hospital, ASK, Patient, LLP, Psychological abuse, Criminal law, Circuit court

CROWNSVILLE, Md., March 1, 2024 /PRNewswire/ -- ASK LLP and Goldman & Van Beek have filed a lawsuit in the Circuit Court for Anne Arundel County on behalf of a former patient of Crownsville State Hospital alleging that she was repeatedly raped and sexually abused by an employee.

Key Points: 
  • CROWNSVILLE, Md., March 1, 2024 /PRNewswire/ -- ASK LLP and Goldman & Van Beek have filed a lawsuit in the Circuit Court for Anne Arundel County on behalf of a former patient of Crownsville State Hospital alleging that she was repeatedly raped and sexually abused by an employee.
  • The alleged horrific abuse occurred when the patient entered the facility in 2006 as a 16-year-old.
  • ASK LLP Partner Judie Saunders filed the lawsuit under Maryland's Child Victims Act along with Maryland attorney John P. Van Beek.
  • "We are accusing the state of Maryland and Crownsville Hospital in engaging in callous segregation practices and for allowing Crownsville's patients to be experimented on, tortured, abused, and neglected."

Moligo Technologies and Nationwide Children's Hospital Collaborate to Advance Cystic Fibrosis Research Using Ultrapure Long Single-Stranded DNA

Retrieved on: 
Tuesday, October 24, 2023
Sequence, Sale, DNA, AAV, Vaidyanathan, CFTR, Research, Reactive airway disease, Risk, Crownsville Hospital Center, Gene, Cystic fibrosis, Nationwide Children's Hospital, Patient, Hospital, CF, B cell, Cystic fibrosis transmembrane conductance regulator, Vaccine

STOCKHOLM, Oct. 24, 2023 /PRNewswire/ -- Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children's Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis (CF) and other airway diseases. Moligo's patent-pending enzymatic DNA production technology delivers ultrapure, long ssDDNA at industrial sale - with the ability to introduce chemical modifications - making it potentially suited as a non-viral delivery method in cell and gene therapies.

Key Points: 
  • STOCKHOLM, Oct. 24, 2023 /PRNewswire/ -- Moligo Technologies announced today that it has signed a collaboration agreement with Nationwide Children's Hospital to provide long, single-stranded DNA for its research into gene therapies for cystic fibrosis (CF) and other airway diseases.
  • While significant advances have been made in gene therapy, using the approach for airway diseases is still in the early stages.
  • Moligo utilizes a proprietary, PCR-free, enzymatic technology to produce ultrapure DNA strands over 10,000 bases long, 100 percent sequence-verified, and at scale.
  • Sequence complexity is also a significant challenge, making encoding many complete and functional long therapeutic genes into ssDNA impossible.

Isolation of Circulating Tumor Cells with TellDx Platform Reveals Potential Mechanism of Resistance to Immune Checkpoint Blockade in Melanoma

Retrieved on: 
Thursday, March 16, 2023
Cancer, Chinese, PD, CR, DRS, Crownsville Hospital Center, CD8, KEAP1, Biomarker, Doctor of Pharmacy, CTC, ICB, Patient, Toxicity, Metastasis, NRF2, Melanoma, Massachusetts General Hospital, NPJ, Harvard Medical School, RNA, Doctor of Philosophy, DOI, Neoplasm, HIV disease progression rates, Vaccine, Medical imaging

BEVERLY, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- TellBio, Inc., a development stage biotechnology company focused on revolutionizing the detection of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces publication of data from the scientific founders that reveal downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade (ICB). The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3).

Key Points: 
  • The paper, titled “Downregulation of KEAP1 in melanoma promotes resistance to immune checkpoint blockade,” was published on March 02, 2023, in NPJ Precision Oncology (DOI 10.1038/s41698-023-00362-3 ).
  • While ICB has significantly improved clinical outcomes in melanoma, a subset of patients do not respond or develop resistance over time.
  • “These exciting data demonstrate that isolation of CTCs from melanoma patients with the TellDx platform and subsequent single cell RNA sequencing can reveal pathways of response and resistance to ICB.
  • Overall, these data provide valuable insights into the mechanisms behind melanoma resistance to immune checkpoint blockade therapy and highlight the potential of monitoring CTCs to improve outcomes of patients with cancer.